Exhibitors Search
MolGenBio Co., Ltd.
|
Exhibition
|
|
|---|---|
|
Booth no.
|
E41 |
|
Country
|
Korea, South |
|
Address
|
1 Gwanak-ro, Gwanak-gu, Seoul, Republic of Korea |
|
Tel
|
<02-6332-1004 |
|
Exhibits
|
합성생물학 기반의 Molecule Through Gene (MtG)는 몰젠바이오의 기술을 집약한 독창적인 신약 개발 플랫폼으로 이를 활용하여 퇴행성 뇌질환 파킨슨병, 알츠하이머병 질병조절 치료제 MG-TA 라이브러리를 개발하였습니다. MG-TA는 상용약물인 면역억제제 FK506 (tacrolimus)의 구조 변경을 통해 표적단백질과의 결합 조절을 활성을 조절할 수 있게 한 신규 물질로서 FK506의 면역억제활성은 거의 제거되고, 우수한 신경재생, 신경보호, alpha-synuclein 응집저해, 항신경염증의 다중 기전의 우수한 파킨슨병 치료 효능을 확인하였습니다(단백질, 세포, 오가노이드, 선충, 제브라피쉬, 마우스 모델 등). 경쟁약물대비 우수한 효능도 확인하였습니다. |
|
Company Type
|
Exhibitor Information
MolGenBio is developing a novel proprietary synthetic biology platform technology targeting intractable diseases such as neurodegenerative diseases and cancer. Our innovative and robust platform technology aims to develop the first/best-in-class small molecule therapeutics by harnessing the expertise in microbial genome scanning, editing and assembly.
Our proprietary MTG (Molecule Through Gene) platform enables us to generate structural derivatives of small molecule drug candidates that are difficult to synthesize through the conventional medicinal chemistry approach.
Our CEO/founder Prof Yoon at Seoul National University elucidated the complete biosynthetic pathway of FK506 for the first time.
MolGenBio team has world-class expertise in tacrolimus R&D/manufacturing.
Our proprietary MTG (Molecule Through Gene) platform enables us to generate structural derivatives of small molecule drug candidates that are difficult to synthesize through the conventional medicinal chemistry approach.
Our CEO/founder Prof Yoon at Seoul National University elucidated the complete biosynthetic pathway of FK506 for the first time.
MolGenBio team has world-class expertise in tacrolimus R&D/manufacturing.
Exhibit/Technology Introduction (General)
MolGenBio is developing a novel proprietary synthetic biology platform technology targeting intractable diseases such as neurodegenerative diseases and cancer. Our innovative and robust platform technology aims to develop the first/best-in-class small molecule therapeutics by harnessing the expertise in microbial genome scanning, editing and assembly. Our proprietary MTG (Molecule Through Gene) platform enables us to generate structural derivatives of small molecule drug candidates that are difficult to synthesize through the conventional medicinal chemistry approach. Our CEO/founder Prof Yoon at Seoul National University elucidated the complete biosynthetic pathway of FK506 for the first time. MolGenBio team has world-class expertise in tacrolimus R&D/manufacturing.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : Development of microbe-derived small molecules with novel therapeutic value via synthetic biology-based structure modifications.MG-TA205 ▷ A novel disease-modifying small molecule with neural regeneration-based combinatorial effects to target neurodegenerative diseases such as Alzheimer’s Disease & Parkinson’s Disease ▷ Robust activation of neural regeneration ▷ Inhibition of toxic protein aggregates (eg. α-synuclein, amyloid-β, tau) ▷ Inhibition of neuroinflammation
KYUNGYON EXHIBITION CORP.